Coherus Oncology

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CHRS and other ETFs, options, and stocks.

About CHRS

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. 

CEO
Denny M. Lanfear
CEODenny M. Lanfear
Employees
147
Employees147
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
2010
Founded2010
Employees
147
Employees147

CHRS Key Statistics

Market cap
229.06M
Market cap229.06M
Price-Earnings ratio
-1.20
Price-Earnings ratio-1.20
Dividend yield
Dividend yield
Average volume
1.86M
Average volume1.86M
High today
$1.51
High today$1.51
Low today
$1.46
Low today$1.46
Open price
$1.49
Open price$1.49
Volume
1.38M
Volume1.38M
52 Week high
$2.62
52 Week high$2.62
52 Week low
$0.71
52 Week low$0.71

Stock Snapshot

With a market cap of 229.06M, Coherus Oncology(CHRS) trades at $1.48. The stock has a price-to-earnings ratio of -1.20.

As of 2026-05-19, Coherus Oncology(CHRS) stock has fluctuated between $1.46 and $1.51. The current price stands at $1.48, placing the stock +1.2% above today's low and -1.8% off the high.

Coherus Oncology(CHRS) shares are trading with a volume of 1.38M, against a daily average of 1.86M.

In the last year, Coherus Oncology(CHRS) shares hit a 52-week high of $2.62 and a 52-week low of $0.71.

In the last year, Coherus Oncology(CHRS) shares hit a 52-week high of $2.62 and a 52-week low of $0.71.

CHRS News

Investing.com 2d
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com

...

Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com
TipRanks 7d
Coherus Biosciences Signals Confident Oncology Earnings Outlook

Coherus Biosciences ((CHRS)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and...

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own CHRS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.